Addition of histone deacetylase inhibitors does not improved prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies

Myelodysplastic syndromes (MDS) are a series of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral blood cytopenias, and a propensity to transform to acute myeloid leukemia (AML) [1]. AML is a myeloid malignancy characterized by increased self-renewal, limited differentiation and deregulated proliferation of myeloid blasts. They may cause bone marrow failure and death within months or even weeks if diagnosis and treatment time is delayed. Recent studies showed that demethylating agents 5-azacytidine (AZA) and 5-aza-2-deoxycytidine (decitabine, DAC) may bring substantial survival benefit for patients with high-risk MDS or AML.

Source: Leukemia Research - June 9, 2018 Category: Hematology Authors: Tingting Pan, Jiaqian Qi, Tao You, Liping Yang, Depei Wu, Yue Han, Li Zhu Source Type: research